Chimerix Company Profile (NASDAQ:CMRX)

Analyst Ratings

Consensus Ratings for Chimerix (NASDAQ:CMRX) (?)
Ratings Breakdown: 1 Sell Rating(s), 10 Hold Rating(s), 2 Buy Rating(s)
Consensus Rating:Hold (Score: 2.08)
Consensus Price Target: $18.82 (350.20% upside)

Analysts' Ratings History for Chimerix (NASDAQ:CMRX)
Show:
DateFirmActionRatingPrice TargetActions
7/17/2016FBR & CoReiterated RatingHoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/29/2016Piper Jaffray Cos.Reiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/1/2016Citigroup Inc.Reiterated RatingHoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/23/2016William BlairLower Price TargetMarket Perform$12.00 -> $8.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/23/2016Barclays PLCDowngradeOverweight -> Equal Weight$12.00 -> $6.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/22/2016Morgan StanleyDowngradeEqual Weight -> Underweight$8.00 -> $5.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/4/2016JPMorgan Chase & Co.DowngradeHoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/3/2016Brean CapitalDowngradeHoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/3/2016Cowen and CompanyDowngradeHoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/3/2016Stifel NicolausDowngradeHoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/30/2015EmpireReiterated RatingEqual WeightView Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/30/2015Janney Montgomery ScottLower Price TargetNeutral$14.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/8/2015Cantor FitzgeraldReiterated RatingBuy$57.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/28/2014 forward)

Earnings

Earnings History for Chimerix (NASDAQ:CMRX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/4/2016        
5/9/2016Q1($0.66)($0.57)$2.79 million$1.20 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/29/2016Q415($0.14)($0.82)$8.07 million$3.10 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/5/2015Q315($0.59)($0.70)$5.01 million$2.27 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/6/2015Q215($0.58)($0.59)$1.37 million$4.10 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/11/2015Q115($0.59)($0.54)$1.19 million$1.20 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/6/2015Q414($0.51)($0.52)$1.20 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/7/2014Q314($0.41)($0.47)$1.19 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/7/2014Q214($0.44)($0.39)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/9/2014Q1 14($0.36)($0.39)$0.85 million$0.78 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/7/2014Q413($0.41)($0.31)$1.19 million$0.88 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/14/2013Q3($0.38)($0.26)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/14/2013Q2 2013($0.40)($0.91)$1.91 million$0.81 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/13/2013Q1 2013($2.43)($22.58)$1.00 million$1.80 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Chimerix (NASDAQ:CMRX)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20164($0.80)($0.45)($0.67)
Q2 20162($0.49)($0.48)($0.49)
Q3 20162($0.42)($0.40)($0.41)
Q4 20162($0.45)($0.38)($0.42)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Chimerix (NASDAQ:CMRX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Chimerix (NASDAQ:CMRX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
6/24/2016Ernest MarioDirectorBuy50,000$3.70$185,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/24/2016M Michelle BerreyCEOBuy13,188$3.69$48,663.72View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/13/2016Ernest MarioDirectorBuy10,000$4.53$45,300.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/11/2016Ernest MarioDirectorBuy25,000$4.85$121,250.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/10/2016Ernest MarioDirectorBuy800$4.76$3,808.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/16/2016Ernest MarioDirectorBuy25,000$5.06$126,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/15/2016Ernest MarioDirectorBuy20,000$5.13$102,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/1/2016Martha J DemskiDirectorBuy10,000$4.89$48,900.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/29/2015Ernest MarioDirectorBuy125,000$7.09$886,250.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/2/2015Martha J. DemskiDirectorSell1,126$41.35$46,560.10View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/1/2015Martha J. DemskiDirectorSell2,000$37.68$75,360.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/1/2015Martha J. DemskiDirectorSell2,000$48.18$96,360.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/21/2015John M LeonardDirectorBuy1,000$47.38$47,380.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/17/2015Timothy W TrostCFOSell28,000$50.00$1,400,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/1/2015Martha J DemskiDirectorSell2,000$46.03$92,060.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/1/2015Martha J DemskiDirectorSell2,000$41.58$83,160.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/1/2015Martha J DemskiDirectorSell2,000$34.71$69,420.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/2/2015Martha J DemskiDirectorSell2,000$40.18$80,360.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/2/2015Martha J DemskiDirectorSell2,000$38.38$76,760.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/2/2015Martha J DemskiDirectorSell2,000$41.08$82,160.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/5/2014John M LeonardDirectorBuy4,000$29.00$116,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/25/2014Timothy W TrostCFOSell5,000$27.75$138,750.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/11/2014James NiedelDirectorSell1,099,949$29.39$32,327,501.11View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/9/2014Sanderling Venture Partners V,Major ShareholderSell122,950$29.28$3,599,976.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/8/2014Timothy WollaegerDirectorSell100,000$24.54$2,454,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/5/2014Ernest MarioDirectorBuy10,000$23.19$231,900.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/25/2014Timothy W TrostCFOSell5,000$25.13$125,650.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/25/2014Timothy W TrostInsiderSell5,000$22.35$111,750.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/25/2014Timothy W TrostCFOSell5,000$22.74$113,700.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/27/2014Ernest MarioDirectorBuy10,000$14.22$142,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/27/2014M Michelle BerreyInsiderBuy14,065$14.22$200,004.30View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/27/2014Timothy W TrostCFOSell5,000$17.41$87,050.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/25/2014Timothy W TrostInsiderSell5,000$18.67$93,350.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/25/2014Timothy W TrostCFOSell5,000$25.37$126,850.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/25/2014Timothy W TrostCFOSell5,000$19.29$96,450.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/27/2014Timothy W TrostCFOSell5,000$18.26$91,300.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/26/2013Timothy W TrostCFOSell5,000$15.21$76,050.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/13/2013Ernest MarioDirectorBuy5,000$13.90$69,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/9/2013Rodman L DrakeDirectorBuy1,000$14.35$14,350.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/25/2013Ernest MarioDirectorBuy8,000$15.20$121,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/19/2013Ernest MarioDirectorBuy7,500$15.25$114,375.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/15/2013Rodman L DrakeDirectorBuy1,000$15.56$15,560.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/25/2013Timothy W TrostCFOSell5,000$16.04$80,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/23/2013Leaf Ventures Ii L.P. NewMajor ShareholderSell585,602$15.51$9,082,687.02View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/23/2013Vii L P CanaanDirectorSell674,771$15.51$10,465,698.21View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/30/2013Ernest MarioDirectorBuy5,064$15.82$80,112.48View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/26/2013Ernest MarioDirectorBuy5,960$17.20$102,512.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/23/2013M Michelle BerreyInsiderBuy5,540$18.70$103,598.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/20/2013Ernest MarioDirectorBuy4,040$17.48$70,619.20View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Chimerix (NASDAQ:CMRX)
DateHeadline
07/22/16 10:34 AMBrokers Issue Average Price Target Of 21.27 On Chimerix, Inc. (CMRX) - Fiscal Standard
07/22/16 10:34 AMChimerix, Inc. (NasdaqGM:CMRX) Fundamental Star Rating Report - CML News
07/19/16 03:23 PMEquity Roundup: Stock Performance Focus on Chimerix, Inc. (NASDAQ:CMRX) - Press Telegraph
07/18/16 12:35 PMETF’s with exposure to Chimerix, Inc. : July 18, 2016 -
07/17/16 07:55 AMWere Analysts Bullish Chimerix Inc (NASDAQ:CMRX) This Week? - Consumer Eagle
07/16/16 05:49 AMShares Experiencing a Downtrend: Chimerix, Inc. (NASDAQ:CMRX) - TGP
07/16/16 05:49 AMChimerix Inc. (CMRX) Jumps 5.51% on July 15 - Equities.com
07/15/16 09:52 AMCrowd Rating and Earnings Recap for Chimerix, Inc. (NASDAQ:CMRX) - Telanagana Press
07/14/16 07:59 AMBroker Outlook For Chimerix, Inc. (CMRX) - Fiscal Standard
07/12/16 07:34 AMTrading Performance and Target Watch for Chimerix, Inc. (NASDAQ:CMRX) - Press Telegraph
07/12/16 07:34 AMChimerix, Inc. (CMRX) Broker Price Targets For The Coming Week - Fiscal Standard
07/07/16 08:33 PMInsiders Increasing Positions in: Chimerix, Inc. (NASDAQ:CMRX) - Press Telegraph
07/07/16 08:33 PMChimerix Inc (NASDAQ:CMRX) First Quarter Institutional Investor Sentiment Steady - Press Telegraph
07/07/16 08:33 PMChimerix Inc. (CMRX) Drops 5.42% on July 05 - Equities.com
07/04/16 03:06 PMBroker Outlook For The Week Ahead Chimerix, Inc. (CMRX) - Fiscal Standard
07/04/16 03:06 PMShare Performance Recap for: Chimerix, Inc. (NASDAQ:CMRX) - Press Telegraph
07/01/16 08:26 PMStock in Action: Chimerix, Inc. (NASDAQ:CMRX) - News Oracle
06/30/16 11:04 AMChimerix, Inc. (NASDAQ:CMRX) Company Rating and Target Watch - Telanagana Press
06/29/16 08:19 PMContraVir Pharmaceuticals : Combination Drugs Moving Quickly to Historic Hepatitis B Cure
06/29/16 03:12 PMContraVir Combination Drugs - Moving Quickly to Historic Hepatitis B Cure
06/29/16 11:23 AMChimerix Inc. (CMRX) Hits New 52-week Low During June 27 Session - Equities.com
06/28/16 08:22 PMContraVir Combination Drugs Moving Quickly To Historic Hepatitis B Cure
06/28/16 08:11 AMBroker Outlook For The Week Ahead Chimerix, Inc. (CMRX) - Fiscal Standard - Financial Market News For Investors ... - Fiscal Standard
06/28/16 05:03 AMCHIMERIX INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders -
06/27/16 03:18 PMNew Broker Ratings For Chimerix, Inc. (CMRX) - FTSE News
06/27/16 03:18 PMChimerix, Inc. (NASDAQ:CMRX) Earnings Glance and Target Price Review - Engelwood Daily
06/27/16 03:18 PMStock Touching a Recent Low: Chimerix, Inc. (NASDAQ:CMRX) - Press Telegraph
06/24/16 07:03 AMChimerix, Inc. (CMRX) Current Analyst Ratings - Fiscal Standard
06/24/16 07:03 AMChimerix Inc. (CMRX) Hits New 52-week Low During June 21 Session - Equities.com
06/20/16 01:14 PMETF’s with exposure to Chimerix, Inc. : June 20, 2016 -
06/19/16 03:06 PMChimerix, Inc. (CMRX) Analyst Price Targets For The Coming Week - Fiscal Standard
06/19/16 07:50 AMChimerix Inc. (CMRX) Hits New 52-week Low During June 16 Session - Equities.com
06/16/16 07:39 AMChimerix Inc. (CMRX) Hits New 52-week Low During June 14 Session - Equities.com
06/14/16 03:11 PMTwo Stocks within Traders Limelight: Mallinckrodt plc (NYSE:MNK) , Chimerix, Inc. (NASDAQ:CMRX) - Street Updates
06/13/16 02:44 PMTrending Stocks Update: Chimerix, Inc. (NASDAQ:CMRX), Gentex Corp. (NASDAQ:GNTX) - Beacon Chronicle
06/13/16 11:14 AMNASDAQ New Lows: Telefonaktiebolaget LM Ericsson (NASDAQ:ERIC), Chimerix, Inc. (NASDAQ:CMRX), ImmunoGen ... - KC Register
06/09/16 03:26 PMOverview of Stock's Trend: Synthetic Biologics, Inc (NYSEMKT:SYN) , Chimerix, Inc. (NASDAQ:CMRX) - Street Updates
06/08/16 11:49 AMTraders Targeted Movers: Centene Corporation (NYSE:CNC) , Chimerix, Inc. (NASDAQ:CMRX) - Street Updates
06/07/16 11:34 AMInvestors Attention Alert: TherapeuticsMD, Inc. (NYSEMKT:TXMD) , Chimerix, Inc. (NASDAQ:CMRX) - Street Updates
06/07/16 07:18 AMChimerix to Participate in Panel on North Carolina's Role in Biodefense Preparation at Medical, Biomedical and Biodefense Symposium - [at noodls] - DURHAM, N.C., June 07, 2016 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company developing novel antivirals in areas of high unmet medical need, today announced that M. Michelle Berrey, ...
06/07/16 07:00 AMChimerix to Participate in Panel on North Carolina’s Role in Biodefense Preparation at Medical, Biomedical and Biodefense Symposium - [GlobeNewswire] - DURHAM, N.C., June 07, 2016-- Chimerix, a biopharmaceutical company developing novel antivirals in areas of high unmet medical need, today announced that M. Michelle Berrey, M.D., M.P.H., President and ...
06/06/16 03:06 PMTrading updates about two Stocks: Alkermes plc (NASDAQ:ALKS) , Chimerix, Inc. (NASDAQ:CMRX) - Street Updates
06/03/16 03:25 PMHow Analysts Feel About Chimerix Inc (NASDAQ:CMRX)? - HNN
06/03/16 03:25 PMEarnings Overview of the Stocks: Chimerix, Inc. (NASDAQ:CMRX), Total System Services, Inc. (NYSE:TSS) - Beacon Chronicle
06/02/16 03:24 PMChimerix, Inc. (NASDAQ:CMRX) Stock Update & Estimates - Stock Tick Tock - Chimerix, Inc. (NASDAQ:CMRX) Stock Update & EstimatesStock Tick TockThe consensus on Wall Street is expecting Chimerix, Inc. (NASDAQ:CMRX) to post earnings of $-0.52 per share when the firm next reports it's fiscal quarterly results. According to the latest information available the report will likely be issued around ...and more »
06/02/16 11:49 AMChimerix Incorporated (NASDAQ:CMRX) Sellers Covered 14.46% of Their Shorts - HNN - Chimerix Incorporated (NASDAQ:CMRX) Sellers Covered 14.46% of Their ShortsHNNThe short interest to Chimerix Incorporated's float is 11.47%. The stock increased 0.41% or $0.02 during the last trading session, hitting $4.92. About 709,509 shares traded hands. Chimerix Inc (NASDAQ:CMRX) has declined 86.30% since October 26, 2015 ...and more »
06/01/16 09:26 PMInsiders Are Gradually Buying Chimerix, Inc. (NASDAQ:CMRX) - HNN - Insiders Are Gradually Buying Chimerix, Inc. (NASDAQ:CMRX)HNNAccording to the latest SEC filings, insiders at Chimerix, Inc. (NASDAQ:CMRX) have increased their position in the stock by 34.85% over the past 6 months. Insiders now own 1.80% of total outstanding shares. There are both legal and illegal types of ...
06/01/16 11:52 AMBuy, Sell Or Hold Rating For Chimerix, Inc. (CMRX)? - Share Trading News - Buy, Sell Or Hold Rating For Chimerix, Inc. (CMRX)?Share Trading News02/23/2016 – Chimerix, Inc. had its “mkt perform” rating reiterated by analysts at FBR Capital Markets. They now have a USD 10 price target on the stock. 02/23/2016 – Chimerix, Inc. was downgraded to “equal-weight” by analysts at Barclays. They now ...
05/31/16 08:59 PMStock Review and Earnings Check on Chimerix, Inc. (NASDAQ:CMRX) - HNN - Stock Review and Earnings Check on Chimerix, Inc. (NASDAQ:CMRX)HNNInvestors and analysts are typically super focused on company earnings numbers when they are reported. Company earnings are a good way to evaluate the company profitability. Currently, sell-side analysts are expecting Chimerix, Inc. (NASDAQ:CMRX) to ...and more »
05/31/16 08:39 AMAnalysts Set 1-Year Price Target Of $8.375 On Chimerix, Inc. (NASDAQ:CMRX) Stock - Investor Newswire - Analysts Set 1-Year Price Target Of $8.375 On Chimerix, Inc. (NASDAQ:CMRX) StockInvestor NewswireSell-side analysts reveal their outlook on Chimerix, Inc. (NASDAQ:CMRX) stock. As of 2016-05-28, the stock has ABR of 2.92. This methodology prompts shareholders to invest in stock if it has a rating of 1. The ABR was known considering the price ...and more »

Social

About Chimerix

Chimerix logoChimerix, Inc. a biopharmaceutical company dedicated to discovering, developing and commercializing oral antivirals. The Company's lipid conjugate technology has developed its lead compound, brincidofovir (BCV, CMX001), which is in Phase III clinical development. It is clinical-stage nucleotide analog lipid-conjugate which has demonstrated potent antiviral activity and safety in convenient, orally administered dosing regimens. In addition, it has an active discovery program focusing on viral targets. CMX157, is its second clinical-stage nucleotide analog, uses the same lipid technology as brincidofovir to deliver high intracellular concentrations of the potent antiviral drug, tenofovir. Tenofovir, marketed under the brand name Viread and in multiple fixed-dose combinations, is used for the treatment of human immunodeficiency virus (HIV) and hepatitis B virus (HBV) infection. It has discovered, developed and selected a clinical candidate, CMX669, for BK virus and cytomegalovirus (CMV).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: CMRX
  • CUSIP:
Key Metrics:
  • Previous Close: $4.18
  • 50 Day Moving Average: $3.96
  • 200 Day Moving Average: $5.38
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $189.47M
  • Beta: 1.42
  • Current Year EPS Consensus Estimate: $-2.07 EPS
  • Next Year EPS Consensus Estimate: $-1.98 EPS
Additional Links:
Chimerix (NASDAQ:CMRX) Chart for Thursday, July, 28, 2016